Sunshine Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	36.31	34.87	24.09	4.35	0.23
Revenue Growth (YoY)	4.11%	44.75%	454.42%	1802.41%	219.88%
Cost of Revenue	24.05	24.2	15.75	2.65	0.12
Gross Profit	12.26	10.67	8.34	1.7	0.11
Selling, General & Admin	15.33	14.94	10.83	9.48	1.87
Research & Development	0.6	0.93	1.86	0.81	0.67
Other Operating Expenses	0.47	0.39	0.29	0.06	-
Operating Expenses	16.73	16.48	13.12	10.37	2.55
Operating Income	-4.48	-5.81	-4.79	-8.67	-2.44
Interest Expense	-	-0.01	-0.14	-0.04	-0.33
Interest & Investment Income	0.28	0.5	0.81	0.52	-
Currency Exchange Gain (Loss)	0	-0.04	-0	-0	0
EBT Excluding Unusual Items	-4.2	-5.37	-4.11	-8.2	-2.77
Impairment of Goodwill	-	-	-	-18.33	-
Gain (Loss) on Sale of Assets	-0.01	-	-	-	-
Asset Writedown	-1.75	-	-	-	-
Other Unusual Items	-	-	-	0.01	-9.67
Pretax Income	-5.95	-5.37	-4.11	-26.51	-12.44
Income Tax Expense	0.02	-0.23	0.4	0.23	-
Earnings From Continuing Operations	-5.98	-5.13	-4.51	-26.74	-12.44
Net Income	-5.98	-5.13	-4.51	-26.74	-12.44
Net Income to Common	-5.98	-5.13	-4.51	-26.74	-12.44
Shares Outstanding (Basic)	4	1	0	-	-
Shares Outstanding (Diluted)	4	1	0	-	-
Shares Change (YoY)	492.39%	5371.73%	-	-	-
EPS (Basic)	-1.44	-7.32	-351.35	-	-
EPS (Diluted)	-1.44	-7.32	-351.35	-	-
Free Cash Flow	-5.51	-14.18	-8.86	-5.44	-1.83
Free Cash Flow Per Share	-1.32	-20.21	-690.63	-	-
Gross Margin	33.76%	30.59%	34.61%	39.04%	48.42%
Operating Margin	-12.34%	-16.67%	-19.86%	-199.61%	-1068.24%
Profit Margin	-16.46%	-14.72%	-18.70%	-615.44%	-5444.41%
Free Cash Flow Margin	-15.16%	-40.67%	-36.76%	-125.24%	-800.75%
EBITDA	-4.15	-5.59	-4.64	-8.65	-2.43
EBITDA Margin	-11.42%	-16.02%	-19.24%	-199.03%	-
D&A For EBITDA	0.33	0.22	0.15	0.03	0.01
EBIT	-4.48	-5.81	-4.79	-8.67	-2.44
EBIT Margin	-12.34%	-16.67%	-19.86%	-199.61%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q